GSK484

GSK484

Translational
-
Preclinical
GSK
Asexual blood stages
Product vision
  • Uncomplicated malaria treatment and resistance management
MOA
  • Novel and unknown
Key features
  • Fast killing in vitro and in vivo
  • No resistant mutants identified
  • Low predicted dose (<100 mg) and 200h predicted half-life
Challenges
  • Human phamacokinetic prediction for low clearance compounds
  • Synthetic route: Palladium used in two chemical steps
Status
  • Photosafety study completed 
  • Pest or pathogen spread modelling
Next milestone
  • Contract signature

  • First-in-human clinical trial application submission

Previously
  • Also known as MMV1793192
Project Director
  • Dr Zaira Rizopoulos